Zynerba Pharmaceuticals, Inc. (ZYNE)
ZYNEPrice: $1.3
Fair Value: 🔒
🔒score
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidio... more
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The com... more
Description
Shares
| Market Cap | $70.12M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Armando Anido MBA |
| IPO Date | 2015-08-05 | CAGR | — |
| Employees | 25 | Website | www.zynerba.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ZYNE chart loading...
Fundamentals
Technicals
| Enterprise Value | $-19.40M | P/E Ratio | -1.65 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 1.2 |
| P/CF Ratio | -2.41 | P/FCF Ratio | -3.02 |
| EPS | $-0.79 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.59% | ROA | -0.63% |
| ROCE | -0.76% | Current Ratio | 5.97 |
| Quick Ratio | 5.97 | Cash Ratio | 5.52 |
| Debt/Equity | 0.01 | Interest Coverage | 163.4 |
| Altman Z Score | -8.89 | Piotroski Score | 2 |